Power Law company profile

BioMarin Pharmaceutical

Biotech & Life Sciences · San Rafael, United States · Founded 1997 · IPO 1999 Unicorn

← All companies

A public taster of the full Dealroom platform — request a demo to explore live financials, founders, funding history, and market intelligence.

Valuation

$9.52B

Market cap · Apr/2026

Revenue

$3.20B

Latest reported FY

Investors

3 investors on BioMarin Pharmaceutical's cap table

Sourced from Dealroom's funding history. Tap any card for that investor's profile.

Series A 3 investors entered at this stage

BBB

Clubb Capital

Genzyme

Patent intelligence

$317M patent portfolio · 124 active families

Total estimated portfolio value via Dealroom Patent Intelligence (Patsnap), with quality scores compared against same-sector peers.

Estimated portfolio value

$317M

3.3% of market cap · comparable to top peer argenx ($275M)

124 active patent families

Where BioMarin Pharmaceutical innovates Molecular biologyDiseaseMedicineOligonucleotideDystrophin

Below peer median on Legal

Quality vs same-sector peers

BioMarin Pharmaceutical on the five Patsnap quality dimensions

BioMarin Pharmaceutical in orange. Same-sector peers are the top filers by total patent value. All scores 0–100; higher is stronger.

Compare against

Patent quality scores (0–100)

Source: Dealroom Patent Intelligence · Patsnap

Tech-focus vs peers

Where BioMarin Pharmaceutical concentrates inside the peer cluster

Axes are the most-shared Patsnap topics across BioMarin Pharmaceutical and its top peers. Each polygon's reach on an axis = how prominent that topic is in that company's portfolio (#1 topic = 100, #10 = 10, absent = 0).

Compare against

Top-topic prominence (rank inverted, 0–100)

Source: Dealroom Patent Intelligence · Patsnap top-10 topics per company

This is teaser data. The full per-sub-category breakdown, individual patent records, and quality-score history are on the Dealroom platform — request a demo to access.

See BioMarin Pharmaceutical on the full Dealroom platform

Live deal flow, founder pedigree, hiring signals, revenue trajectory, and the full cap table.

Open in Dealroom Book a demo